A new cost analysis finds that matching relapsed lymphoma treatment to a personalized drug-response test was associated with longer disease control and a lower estimated daily treatment cost in dogs.
|Articles|February 23, 2011
Today's Daily Dose: Transitional cell carcinoma
A treatment tip for dogs.
Advertisement
Untitled Document
“One of the standard recommendations for dogs with transitional cell carcinoma (TCC) is the use of the NSAID piroxicam. In a pilot study, it was found that 20 percent of dogs with bladder tumors treated with piroxicam alone had a partial or complete response.”
Advertisement
Advertisement
Related to this article
Verdinexor tablets are now available for dogs with lymphoma after receiving full FDA approval earlier this year, offering an at-home treatment option given twice weekly and showing a longer time to disease progression than the control in a field study.
Preclinical testing at The Ohio State University found Telomir-Zn inhibited the growth of canine and human osteosarcoma cell lines, prompting the company to explore a possible in vivo study in dogs with naturally occurring tumors.
Caroline Cox, LSW, MSW, and Erika Krick, VMD, DACVIM (Oncology), discuss the role of veterinary social workers in supporting clients, communicating with veterinary teams, and helping practices address the human side of veterinary care in this Q&A from an interview at the 2026 Fetch National Harbor Veterinary Conference.
Advertisement
Advertisement
Trending on dvm360
1
Saline injection lot recalled after potassium chloride bag found in mislabeled wrap
2
FAQs: Rising rabies exposure calls put PEP decisions back in focus
3
Pet Poison Helpline reports rise in Apoquel calls
4
AAVMC and Chewy Health open nominations for 2027 veterinary student leadership scholarships
5